Vector, Per Se (e.g., Plasmid, Hybrid Plasmid, Cosmid, Viral Vector, Bacteriophage Vector, Etc.) Bacteriophage Vector, Etc.) Patents (Class 435/320.1)
-
Patent number: 11447753Abstract: Provided herein are compositions and methods for vaccination and research applications. In particular, provided herein are non-neuroinvasive herpesviruses and alpha herpesviruses and uses thereof.Type: GrantFiled: May 6, 2020Date of Patent: September 20, 2022Assignees: Northwestern University, Board of Regents of the University of Nebraska, Trustees of Tufts College (AKA Tufts University)Inventors: Gregory A. Smith, Patricia Jane Sollars, Gary Edward Pickard, Ekaterina E. Heldwein
-
Patent number: 11440954Abstract: Described herein are humanized anti-TL1A antibodies and pharmaceutical compositions for the treatment of inflammatory bowel disease (IBD), such as Crohn's Disease (CD) and ulcerative colitis (UC).Type: GrantFiled: April 30, 2020Date of Patent: September 13, 2022Assignees: Prometheus Biosciences, Inc., Cedars-Sinai Medical CenterInventors: Jeffry D. Watkins, Cindy T. Dickerson, J. Monty Watkins, Patricia McNeeley, Janine Bilsborough, Bradley Henkle, Stephan R. Targan
-
Patent number: 11441150Abstract: An expression enhancer comprising a CPMV 5?UTR nucleotide sequence consisting of X nucleotides (CMPVX), where X=160, 155, 150, or 114 of SEQ ID NO:1, or consisting of a nucleotide sequence comprising from about 80% to 100% sequence similarity with CMPVX, where X=160, 155, 150, or 114 of SEQ ID NO:1 SEQ ID NO:1 is provided. The expression enhancer may further comprise a stuffer sequence fused to the 3? end of the 5?UTR nucleotide sequence (CMPVX+, where X=160, 155, 150, or 114 of SEQ ID NO:1). The stuffer sequence may comprise one or more plant kozak sequences. Plants comprising the expression enhancer and methods using the expression enhancer are also described.Type: GrantFiled: January 8, 2015Date of Patent: September 13, 2022Assignee: Medicago Inc.Inventors: Pierre-Olivier Lavoie, Marc-Andre D'Aoust
-
Patent number: 11434493Abstract: The invention provides important tools for the use of Chlorophyte organisms, including regulatory sequences useful for the expression of transgenes in such organisms. Also provided are vectors and expression cassettes containing promoters and/or terminators disclosed herein for expression of transgenes in Chlorophyte organisms. Methods of using these tools are also provided.Type: GrantFiled: February 4, 2021Date of Patent: September 6, 2022Assignee: Viridos, Inc.Inventors: John Verruto, Moena Aqui
-
Patent number: 11426469Abstract: The disclosure relates to compositions and methods for rAAV-mediated delivery of a transgene to a subject. In some embodiments, the rAAV transduces the prostate tissue of a subject. In some embodiments, the methods are useful for treatment of prostate disease (e.g., prostatitis, BPH, prostate cancer).Type: GrantFiled: October 21, 2016Date of Patent: August 30, 2022Assignee: University of MassachusettsInventors: Guangping Gao, Jianzhong Ai, Hong Li, Qiang Wei
-
Patent number: 11427835Abstract: Recombinant viral vectors such as AAV vectors designed with expression cassettes that approach the natural packaging capacity of the virus, such as AAV are provided. The recombinant viral vectors reduce residual plasmid DNA impurities.Type: GrantFiled: March 14, 2014Date of Patent: August 30, 2022Assignee: The Children's Hospital of PhiladelphiaInventors: J. Fraser Wright, Olga Zelenaia
-
Patent number: 11427810Abstract: The present invention relates to an oncolytic virus comprising: (i) a fusogenic protein-encoding gene; and (ii) an immune stimulatory molecule-encoding gene.Type: GrantFiled: February 24, 2020Date of Patent: August 30, 2022Assignee: Replimune LimitedInventor: Robert S. Coffin
-
Patent number: 11421017Abstract: The present invention relates to a recombinant herpes simplex virus (HSV) containing an expression cassette capable of expressing a fused protein of a cancer-cell-targeting domain and an extracellular domain of HVEM and the use thereof. When the recombinant HSV infects and enters target cells, which are cancer cells, HSV proliferates, and an adapter, which is the fused protein, is expressed in the cells and is released to the outside of the cells along with the proliferated HSV virion upon cell lysis, or is released even before the virion is released due to cell lysis when the adapter contains a leader sequence, and the fused protein released to the outside of the cells acts to induce the HSV virion to infect surrounding cancer cells expressing a target molecule recognized by the cancer-cell-targeting domain or to increase the infection efficiency thereof.Type: GrantFiled: August 21, 2020Date of Patent: August 23, 2022Assignees: GENCELLMED INC., KOREA INSTITUTE OF RADIOLOGICAL & MEDICAL SCIENCESInventors: Heechung Kwon, Hyunjung Baek, Hyun Yoo Joo
-
Patent number: 11421242Abstract: The compositions and methods disclosed relate to DNA compositions, plant cells, seeds, plant parts that relate to maize plants with increased grain yield trait. Also provided are assays for detecting the presence of the maize DP-202216-6 event based on the DNA sequence of the recombinant construct inserted into the maize genome and the DNA sequences flanking the insertion site. Kits and conditions useful in conducting the assays are provided.Type: GrantFiled: April 16, 2019Date of Patent: August 23, 2022Inventors: Heather Marie Christensen, Nathan David Coles, Olga Danilevskaya, Jeffrey Habben, Mary A Rupe, Jeffrey R Schussler, Bo Shen, Benjamin P Weers, Jingrui Wu
-
Patent number: 11414679Abstract: The present invention relates to isolated polynucleotide and polypeptide sequences derived from novel chimpanzee adenovirus ChAd157, as well as to recombinant polynucleotides, vectors, adenoviruses, cells and compositions comprising said polynucleotide and polypeptide sequences.Type: GrantFiled: December 7, 2017Date of Patent: August 16, 2022Assignee: GLAXOSMITHKLINE BIOLOGICALS SAInventors: Virginia Ammendola, Stefania Capone, Stefano Colloca, Antonella Folgori, Rossella Merone
-
Patent number: 11396663Abstract: Sequences of a serotype 8 adeno-associated virus and vectors and host cells containing these sequences are provided. Also described are methods of using such host cells and vectors in production of rAAV particles.Type: GrantFiled: April 8, 2019Date of Patent: July 26, 2022Assignee: The Trustees of the University of PennsylvaniaInventors: Guangping Gao, James M. Wilson, Mauricio R. Alvira
-
Patent number: 11390661Abstract: Subject matter of the present invention is a soluble PDGFR-alpha-Fc chimera or a PDGFR-alpha derived peptide or an anti-PDGFR-alpha antibody or a PDGFR-alpha antibody fragment or anti-PDGFR-alpha non-Ig scaffold for inhibiting HCMV entry for use in a method of treatment in a subject that has been infected by HCMV or for use in a method of prophylaxis of HCMV infection in a subject that has not yet been infected by HCMV.Type: GrantFiled: June 27, 2017Date of Patent: July 19, 2022Assignee: AiCuris Anti-Infective Cures GmbHInventors: Christian Sinzger, Cora Stegmann, Kerstin Laib Sampaio, Barbara Adler
-
Patent number: 11390881Abstract: The present invention provides for soybean plant and seed comprising transformation event MON89788 and DNA molecules unique to these events. The invention also provides methods for detecting the presence of these DNA molecules in a sample.Type: GrantFiled: July 1, 2020Date of Patent: July 19, 2022Assignee: MONSANTO TECHNOLOGY, LLCInventors: Marianne Malven, Jennifer Rinehart, Nancy Taylor, Ellen Dickinson
-
Patent number: 11390670Abstract: Described herein are antibodies that target Leukemia Inhibitory Factor (LIF). Also described herein are uses of these antibodies for the treatment of cancer.Type: GrantFiled: December 18, 2017Date of Patent: July 19, 2022Assignees: MEDIMMUNE LIMITED, FUNDACIO PRIVADA INSTITUT D'INVESTIGACIO ONCOLOGIC, FUNDACIO PRIVADA INSTITUCIO CATALANA DE RECERCA IInventors: Joan Seoane Suarez, Judit Anido Folgueira, Johan Fransson, Jean-Philippe Julien, Swetha Raman
-
Patent number: 11377669Abstract: Adeno-associated virus rh.20 sequences, vectors containing same, and methods of use are provided.Type: GrantFiled: October 12, 2021Date of Patent: July 5, 2022Assignee: The Trustees of the University of PennsylvaniaInventors: Guangping Gao, James M. Wilson, Mauricio R. Alvira
-
Patent number: 11376316Abstract: Methods for generating immune responses using adenovirus vectors that allow multiple vaccinations with the same adenovirus vector and vaccinations in individuals with preexisting immunity to adenovirus are provided.Type: GrantFiled: September 14, 2016Date of Patent: July 5, 2022Assignee: Etubics CorporationInventors: Joseph P. Balint, Frank R. Jones, Richard B. Gayle
-
Patent number: 11376338Abstract: Provided herein, among other things, is a method for producing an RNA product that has reduced immunogenicity. In some embodiments, the method involves transcribing a template DNA with a thermostable RNA polymerase at a temperature of greater than 44° C.Type: GrantFiled: June 12, 2018Date of Patent: July 5, 2022Assignee: New England Biolabs, Inc.Inventors: Bijoyita Roy, G. B. Robb
-
Patent number: 11377663Abstract: Polynucleotides comprising genetic regulatory elements, as well as constructs, host cells, and transgenic organisms comprising the same are described. The polynucleotides can control the expression of an operably linked gene in a host cell or organism, such as a plant cell or a plant. Methods of using the polynucleotide to control the expression of an operably linked gene of interest in a plant or plant cell are further provided.Type: GrantFiled: August 30, 2012Date of Patent: July 5, 2022Assignee: Monsanto Technology LLCInventors: Ian W. Davis, Tedd D. Elich
-
Patent number: 11369096Abstract: The present invention relates to processes for transfecting cells. In particular, the present invention relates to processes for using CRISPR to incorporate a polynucleotide into the genome of an avian primordial germ cell (PGC).Type: GrantFiled: April 15, 2019Date of Patent: June 28, 2022Assignees: COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION, AVIAGENInventor: Scott Geoffrey Tyack
-
Patent number: 11369650Abstract: The present invention is related to the use of a virus, preferably an adenovirus for reversing resistance in cells.Type: GrantFiled: March 17, 2017Date of Patent: June 28, 2022Inventor: Per Sonne Holm
-
Patent number: 11353400Abstract: Disclosed herein are methods of detecting a target nucleic acid sequence, determining the localization of the target nucleic acid sequence, and/or quantifying the number of target nucleic acid sequences in a cell. This method may be used on small target nucleic acid sequences, and may be referred to as Nano-FISH.Type: GrantFiled: July 19, 2017Date of Patent: June 7, 2022Assignee: Altius Institute for Biomedical SciencesInventors: John A. Stamatoyannopoulos, Shreeram Akilesh, Vivek Nandakumar
-
Patent number: 11345945Abstract: The present invention provides a polypeptide comprising an N-terminal polypeptide domain having luciferase activity and a C-terminal polypeptide domain having VAMP1, VAMP2 or VAMP3 activity where VAMP stands for vesicle-associated membrane protein. Corresponding nucleic acid molecules, expression vectors and genetically modified cells are also provided. The invention also provides methods and uses of the same.Type: GrantFiled: February 14, 2018Date of Patent: May 31, 2022Assignee: The University Of SheffieldInventors: Bazbek Davletov, Andrew Alexander Peden, Aleksander Mikael Rudolf Rust, Ciara Louise Doran
-
Patent number: 11339406Abstract: The present invention relates to variants of acid-alpha glucosidase and uses thereof.Type: GrantFiled: September 12, 2017Date of Patent: May 24, 2022Assignees: GENETHON, INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), UNIVERSITE D'EVRY VAL D'ESSONNEInventors: Federico Mingozzi, Giuseppe Ronzitti
-
Patent number: 11331343Abstract: Chimeric poliovirus is capable of activating antigen presenting cells. The activation of the antigen presenting cells may be in vitro, ex vivo, or in vivo. The activated antigen presenting cells may be administered alone or with an antigen or vaccine. The activated antigen may be loaded in vitro or ex vivo with antigen to form antigen-loaded, activated, antigen presenting cells. These may be administered therapeutically. Therapeutic administration of antigen presenting cells may be used as an adjuvant to other therapies.Type: GrantFiled: June 29, 2017Date of Patent: May 17, 2022Assignee: Duke UniversityInventors: Smita Nair, Michael Brown, Darell Bigner, Matthias Gromeier
-
Patent number: 11332729Abstract: This disclosure relates to modified tryptophan synthase and more particularly to modified beta-subunits of tryptophan synthase. The disclosure further relates to cells expressing such modified subunits and methods of producing non-canonical amino acids.Type: GrantFiled: August 24, 2017Date of Patent: May 17, 2022Assignee: California Institute of TechnologyInventors: David K. Romney, Javier Murciano Calles, Jori E. Wehrmuller
-
Patent number: 11325956Abstract: Disclosed are materials and methods for treating diseases of the mammalian eye, and in particular, Usher syndrome 1B (USH1B). The invention provides AAV-based, dual-vector systems that facilitate the expression of full-length proteins whose coding sequences exceed that of the polynucleotide packaging capacity of an individual AAV vector. In one embodiment, vector systems are provided that include i) a first AAV vector polynucleotide that includes an inverted terminal repeat at each end of the polynucleotide and a suitable promoter followed by a partial coding sequence that encodes an N-terminal portion of a full-length polypeptide; and ii) a second AAV vector polynucleotide that includes an inverted terminal repeat at each end of the polynucleotide and a partial coding sequence that encodes a C-terminal portion of a full-length polypeptide, optionally followed by a polyadenylation (pA) signal sequence.Type: GrantFiled: February 1, 2019Date of Patent: May 10, 2022Assignee: University of Florida Research Foundation, IncorporatedInventors: Sanford L. Boye, Shannon E. Boye, Frank Dyka, William W. Hauswirth
-
Patent number: 11306322Abstract: The present invention refers to a method for controlling undesired vegetation at a plant cultivation site, the method comprising the steps of providing, at said site, a plant that comprises at least one nucleic acid comprising a nucleotide sequence encoding a wild-type or a mutated protoporphyrinogen oxidase (PPO) which is resistant or tolerant to a PPO-inhibiting herbicide by applying to said site an effective amount of said herbicide. The invention further refers to plants comprising wild-type or mutated PPO enzymes, and methods of obtaining such plants.Type: GrantFiled: April 23, 2019Date of Patent: April 19, 2022Assignee: BASF AGRO B.V.Inventors: Raphael Aponte, Stefan Tresch, Matthias Witschel, Jens Lerchl, Dario Massa, Tobias Seiser, Thomas Mietzner, Jill Marie Paulik, Chad Brommer
-
Patent number: 11306325Abstract: The present invention provides recombinant adenoviral vectors, immunogenic compositions thereof and their uses in medicine. In particular, the present invention provides an adenoviral vector comprising the genome of an adenovirus other than AdHu5 and AdY25, wherein the genome of the adenovirus has been modified such that the vector lacks the native E4 locus of the adenovirus and comprises heterologous E4Orf1, E4Orf2 and E4Orf3 coding regions from AdY25.Type: GrantFiled: June 23, 2017Date of Patent: April 19, 2022Assignee: Oxford University Innovation LimitedInventors: Sarah C. Gilbert, Adrian V S Hill, Matthew G. Cottingham, Matthew Dicks, Susan J. Morris, Alexander Douglas
-
Patent number: 11306324Abstract: Provided herein are methods of delivering “split” Cas9 protein or nucleobase editors into a cell, e.g., via a recombinant adeno-associated virus (rAAV), to form a complete and functional Cas9 protein or nucleobase editor. The Cas9 protein or the nucleobase editor is split into two sections, each fused with one part of an intein system (e.g., intein-N and intein-C encoded by dnaEn and dnaEc, respectively). Upon co-expression, the two sections of the Cas9 protein or nucleobase editor are ligated together via intein-mediated protein splicing. Recombinant AAV vectors and particles for the delivery of the split Cas9 protein or nucleobase editor, and methods of using such AAV vectors and particles are also provided.Type: GrantFiled: October 13, 2017Date of Patent: April 19, 2022Assignee: President and Fellows of Harvard CollegeInventors: David R. Liu, Jonathan Ma Levy, Wei Hsi Yeh
-
Patent number: 11298414Abstract: Two-component vaccine formulations and methods are contemplated where the vaccine has an adjuvant component and a therapeutic component. The therapeutic component comprises preferably a recombinant therapeutic virus encoding a therapeutic antigen while the adjuvant component comprises a non-host cell or immune stimulating portion thereof. Notably, use of the adjuvant component will result in significant uptake of the therapeutic component into immune competent cells, even in the absence of receptors for entry of the therapeutic component. In addition, such adjuvant also stimulates expression of the therapeutic antigen.Type: GrantFiled: August 9, 2019Date of Patent: April 12, 2022Assignee: NantBio, Inc.Inventors: Kayvan Niazi, Raymond Wong, Peter Sieling, Philip T. Liu
-
Patent number: 11279945Abstract: Isolated cDNA sequences encoding for highly conserved domains of plant viral pathogen genomes. The cDNA sequences are selected from the group consisting of those listed in Table I (SEQ ID NOs: 1-68). cDNA fusion constructs or chimeric transgene constructs comprising at least two different cDNA sequences selected from the list in Table I, and more specifically cDNA corresponding to at least two different viruses is described, along with methods of creating transgenic plants with broad-spectrum, durable resistance to multiple viral pathogens using these cDNA sequences.Type: GrantFiled: May 4, 2017Date of Patent: March 22, 2022Assignees: Kansas State University Research Foundation, Heartland Plant Innovations, Inc.Inventors: Dorith Rotenberg, Anna E. Whitfield, William W. Bockus, Forrest G. Chumley, Rodolfo Acosta-Leal
-
Patent number: 11280790Abstract: The activity of a number of therapeutic antibodies is mediated in part by antibody-dependent cell-mediated cytotoxicity (ADCC). An engineered effector cell line expressing the low affinity Fc receptor, Fc?R111a (CD16), that responds to ligation of the Fc moiety of antibody bound to the specific antigen expressed on target cells by activation of a NFAT responsive reporter gene is described. In this cell line the firefly luciferase (FL) reporter gene is regulated by a novel synthetic chimeric promoter containing binding sites for NF-AT, AP1, NFkB, and STAT5 that confers improved sensitivity, an improved dynamic range, an improved tolerance to human serum and a reduced incubation time, relative to engineered effector cell lines that express a NFAT regulated reporter-gene, when used in an ADCC assay together with engineered target cells.Type: GrantFiled: March 10, 2017Date of Patent: March 22, 2022Assignee: SVAR LIFE SCIENCE ABInventors: Michael Tovey, Christophe Lallemand
-
Patent number: 11266171Abstract: The present invention provides a process for producing a food ingredient or beverage ingredient. The present invention also provides a process for producing food product or beverage product. The present invention also provides a process for providing starch, amylose, amylopectin, ?-glucan, fructan, non-starch polysaccharide, dietary fibre or resistant starch to improve one or more indicators of health in a mammal.Type: GrantFiled: February 8, 2019Date of Patent: March 8, 2022Assignee: THE HEALTHY GRAIN PTY LIMITEDInventors: Zhongyi Li, Matthew Kennedy Morell, Stephen Alan Jobling
-
Patent number: 11268103Abstract: This disclosure provides transgenic plants having enhanced traits such as increased yield, enhanced nitrogen use efficiency and enhanced drought tolerance; propagules, progeny and field crops of such transgenic plants; and methods of making and using such transgenic plants. This disclosure also provides methods of producing hybrid seed from such transgenic plants, growing such seed and selecting progeny plants with enhanced traits. Also disclosed are transgenic plants with altered phenotypes which are useful for screening and selecting transgenic events for the desired enhanced trait.Type: GrantFiled: March 6, 2013Date of Patent: March 8, 2022Assignee: Monsanto Technology LLCInventors: Paolo Castiglioni, Jaishree M. Chittoor-Vijayanath, Barry S. Goldman, Robert J. Meister, Monnanda S. Rajani, G. Ramamohan, Naveen Silvester, Tyamagondlu V. Venkatesh, Jingrui Wu, Xiaoyun Wu
-
Patent number: 11261455Abstract: The present invention provides plant virus vectors developed from the Sugarcane mosaic virus (SCMV). The vectors include a nucleic acid sequence encoding an infectious Sugarcane mosaic virus (SCMV) operably linked to one or more regulatory elements functional in a plant. The plant virus vectors may be used to infect monocot plants, such as maize, for gene expression applications.Type: GrantFiled: May 18, 2020Date of Patent: March 1, 2022Assignee: Iowa State University Research Foundation, Inc.Inventors: John Hemmingson Hill, Steven Alan Whitham, Yu Mei, Chunquan Zhang
-
Patent number: 11254944Abstract: The present invention relates to a nanocarrier peptide sequence (SEQ ID NO: 6 KXPXXXXA/V/GXGNXX; wherein X is selected from amino acid R, K, A or H. The present invention also relates to the method for cellular delivery, by implementing the steps of: complexation of a peptide nanocarrier sequence: KXPXXXXA/V/GXGNXX; where X is selected from amino acid R,K,A and H having SEQ ID NO: 6 with a macromolecule to obtain a complex; and administering the complex to a targeted mammalian or plant cell or tissue.Type: GrantFiled: October 7, 2019Date of Patent: February 22, 2022Assignee: INDIAN INSTITUTE OF TECHNOLOGY DELHIInventors: Archana Chugh, Aastha Jain, Mudit Mishra
-
Patent number: 11246905Abstract: The present disclosure provides, in some embodiments, compositions, kits, systems, and methods for reducing bacteria on a surface (e.g., a medical device) and preventing and/or treating a bacterial infection (e.g., urinary tract infection) in a subject using IdsD protein or a fragment thereof.Type: GrantFiled: August 14, 2017Date of Patent: February 15, 2022Assignee: President and Fellows of Harvard CollegeInventors: Karine Gibbs, Christina Caroline Saak
-
Patent number: 11248270Abstract: The present invention provides a method of detecting one or more Klebsiella species within a sample from a subject, the method comprising: subjecting DNA and/or RNA from the sample to a PCR amplification reaction using primer pairs targeting species-specific canonical single nucleotide polymorphisms (canSNPs); and analyzing amplification products resulting from the PCR amplification reaction to detect the one or more Klebsiella species. The present invention also provides a kit for detection of one or more Klebsiella species, Klebsiella clonal groups, AMR genes, and/or virulence genes, the kit comprising primer pairs targeting species-specific canSNPs, K. pneumoniae genes M1 and M2, clonal group-specific canSNPs, AMR genes, and/or virulence genes.Type: GrantFiled: March 14, 2017Date of Patent: February 15, 2022Assignees: The Translational Genomics Research Institute, Arizona Board of Regents on behalf of Northern Arizona UniversityInventors: Jolene Bowers, Elizabeth Driebe, David Engelthaler, Paul Keim, Darrin Lemmer
-
Patent number: 11242530Abstract: Provided are a human PD-1 knockdown siRNA, a recombinant expression CAR-T vector, a preparation method thereof, and an application of the same. A PD-1 knockdown siRNA expression cassette and an siRNA expression product thereof can be applied to a CAR-T therapy of multiple myeloma (MM) for eliminating or alleviating a tumor immune escape mechanism, and in the suppression of an immune escape mechanism in a CAR-T therapy of a tumor, such as pancreatic cancer, brain glioma, and myeloma.Type: GrantFiled: November 13, 2017Date of Patent: February 8, 2022Assignee: SHANGHAI UNICAR-THERAPY BIO-MEDICINE TECHNOLOGY CO., LTDInventors: Lei Yu, Liqing Kang, Zhou Yu
-
Patent number: 11230574Abstract: A heterologous expression cassette, DNA construct and vaccine composition for immunization against flavivirus and/or other pathogens. DNA constructs, recombinant viruses and vaccine compositions containing the recombinant viruses were obtained. This invention also concerns and provide an improved expression vector of the live-attenuated yellow fever 17D virus. Modifications in the expression cassette of heterologous proteins in the intergenic E/NS1 region of the yellow fever 17D vaccine virus, were made. The two new functional domains inserted in the expression cassette were (1) a coding sequence for the N-glycosylation motif, located between the NS1 N-terminal motif and the heterologous protein and (2) a sequence which promoted the proteolytic cleavage, or not, of the recombinant protein in such a way as to release it from its C-terminal containing the transmembrane domains and, consequently, from its association with the membrane of the endoplasmatic reticulum—ER.Type: GrantFiled: August 4, 2017Date of Patent: January 25, 2022Assignee: FUNDAÇÃO OSWALDO CRUZInventors: Myrna Cristina Bonaldo, Noemia Santana Lima
-
Patent number: 11230699Abstract: Provided are genetically modified NK cells expressing a chimeric antigen receptor targeting an EGFR superfamily receptor. The CAR can comprise an intracellular domain of Fc?RI? and further recombinant proteins expressed by the genetically modified NK cells are CD16, autocrine growth stimulating cytokines, and optionally one of IL-12, a TGF-beta trap, or a homing receptor. Also described are methods for treating a patient having or suspected of having a disease that is treatable with NK-92 cells, such as cancer, comprising administering to the patient the genetically modified NK cells.Type: GrantFiled: January 28, 2020Date of Patent: January 25, 2022Assignee: ImmunityBio, Inc.Inventors: John H. Lee, Laurent H. Boissel, Hans G. Klingemann
-
Patent number: 11224181Abstract: The present invention relates to methods for controlling hybridization in plants and producing hybrid plants. The present invention also relates to nucleic acids encoding amino acid sequences for self-incompatibility (SI) proteins in plants, and the use thereof for the manipulation of SI, including seed production, in plants, particularly of the Poaceae family. The present invention also relates to kits, compositions, constructs and vectors including such nucleic acids, and related polypeptides, regulatory elements and methods. The present invention also relates to expression of self-gamete recognition genes in plants and to related nucleic acids, constructs, molecular markers and methods.Type: GrantFiled: April 25, 2019Date of Patent: January 18, 2022Assignees: Agriculture Victoria Services PTY LTD, Dairy Australia LimitedInventors: Hiroshi Shinozuka, Noel Cogan, John White Forster, German Carlos Spangenberg, Nicola Patron, Yidong Ran, Luke Pembleton
-
Patent number: 11219636Abstract: Provided are nucleic acid constructs and systems which comprise (i) a first nucleic acid construct encoding a toxin operatively linked to a first promoter and at least one cancer-associated signaling responsive enhancer element; and (ii) a second nucleic acid construct encoding an anti-toxin operatively linked to a second promoter, the second promoter being stronger than the first promoter. Also provided are pharmaceutical compositions comprising same and methods of using same for treating cancer.Type: GrantFiled: May 17, 2016Date of Patent: January 11, 2022Assignee: THE MEDICAL RESEARCH, INFRASTRUCTURE AND HEALTH SERVICES FUND OF THE TEL AVIV MEDICAL CENTERInventors: Nadir Arber, Shiran Shapira, Dina Kazanov
-
Patent number: 11208665Abstract: Compositions and methods for improving plastid transformation in difficult to transform plants are disclosed.Type: GrantFiled: July 9, 2019Date of Patent: December 28, 2021Assignee: RUTGERS, THE STATE UNIVERSITY OF NEW JERSEYInventor: Pal Maliga
-
Patent number: 11203765Abstract: Described are methods and compositions for enhancing drought tolerance in plants. Nucleic acid constructs therefore are also described. Transgenic plants are also provided that exhibit enhanced agronomic properties. The inventors have demonstrated increased drought tolerance in connection with increased expression of the Xa21 gene.Type: GrantFiled: November 12, 2018Date of Patent: December 21, 2021Assignee: University of Florida Research Foundation, IncorporatedInventors: Wen-Yuan Song, Xiuhua Chen, Xiaoen Huang
-
Patent number: 11186643Abstract: Antibodies which specifically bind to the Axl protein are described. Also disclosed are methods for the production and use of the anti-Axl antibodies.Type: GrantFiled: April 20, 2018Date of Patent: November 30, 2021Assignee: BerGenBio ASAInventors: David Robert Micklem, Sergej Kiprijanov, Linn Hodneland Nilsson, Lavina Ahmed, Hallvard Haugen
-
Patent number: 11173196Abstract: The present disclosure provides (a) vectors comprising a multi-antigen construct encoding two, three, or more immunogenic PAA polypeptides; (b) compositions comprising the vectors, (c) methods relating to uses of the vectors and compositions for eliciting an immune response or for treating prostate cancers.Type: GrantFiled: August 23, 2018Date of Patent: November 16, 2021Assignee: Pfizer Inc.Inventor: Joseph John Binder
-
Patent number: 11174486Abstract: Some embodiments described herein relate to cells which have been genetically engineered to release a polypeptide when a population of the cells reaches a desired density. In some embodiments, the released polypeptide may be a therapeutic polypeptide. In some embodiments, the therapeutic polypeptide kills tumor cells or which inhibits the growth of tumor cells.Type: GrantFiled: April 7, 2016Date of Patent: November 16, 2021Assignees: The Regents of the University of California, Massachusetts Institute of TechnologyInventors: Jeff Hasty, Lev Tsimring, Muhammad Omar Din, Arthur Prindle, Sangeeta Bhatia, Tal Danino
-
Patent number: 11173186Abstract: A method of treating a human patient comprising systemically administering multiple doses of a parenteral formulation of a replication capable oncolytic adenovirus of subgroup B in a single treatment cycle, wherein the total dose given in each dose is in the range of 1×1010 to 1×1014 viral particles, and wherein each dose of virus is administered over a period of 1 to 90 minutes, for example at a rate of viral particle delivery in the range of 2×1010 particles per minute to 2×1012 particles per minute. Also provided are formulations of the oncolytic adenoviruses and combination therapies of the viruses and formulations with other therapeutic agents.Type: GrantFiled: June 12, 2014Date of Patent: November 16, 2021Assignee: PSIOXUS THERAPEUTICS LIMITEDInventors: John William Beadle, Kerry Fisher, Christine Wilkinson Blanc
-
Patent number: 11160244Abstract: The present invention relates to novel plants, in particular to pepper plants capable of producing fruits which can be kept a longer period of time on the plant as well as being stored after harvesting under refrigerated conditions without exhibiting excessive softening. The invention thus refers to pepper plant which produces fruits with significantly increased fruit firmness at the harvesting stage, wherein said increased fruit firmness is controlled by a genetic determinant, monogenic, wherein said increased fruit firmness is defined as a fruit deformation under a 1 kg load force that is lower than that of a fruit from a control pepper plant which does not have the said genetic determinant.Type: GrantFiled: March 31, 2016Date of Patent: November 2, 2021Assignee: YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD.Inventor: Yonatan Elkind